Skip to main content

Table 2 Comparison of demographic, epidemiological and clinical variables between positive and negative HPV patients

From: Italian observational study on HPV infection, E6, and p16 expression in men with penile cancer

  HPV negativity HPV positivity P value
Mean age (SD), years 69.6 (10.6) 64.1 (13.7) 0.24
Age ≥ 55 years, n (%) 21/23 (91.3) 7/9 (77.8) 0.56
Civil status, n (%)
Married 8/12 (66.7) 5/5 (100.0) 0.34
Single 2/12 (16.7) 0/5 (0.0)
Widower 2/12 (16.7) 0/5 (0.0)
Occupational status, n (%)
Employed 5/12 (41.7) 2/6 (33.3) 0.73
Retired 7/12 (58.3) 4/6 (66.7)
Familiarity for carcinoma, n (%) 1/11 (9.1) 0/4 (0.0) 1.0
Suspected diagnosis of carcinoma, n (%) 16/17 (94.1) 7/8 (87.5) 1.0
Cancer diagnosed before 2010, n (%) 7/23 (30.4) 3/9 (33.3) 1.0
Anatomic site, n (%)
Glans 18/23 (78.3) 6/9 (66.7) 1.0
Penis 5/23 (21.7) 3/9 (33.3) 1.0
Histopathological results, n (%)
Squamous Cell Carcinoma 23/23 (100.0) 7/9 (77.8) 0.07
Hyperplasia 0/23 (0.0) 1/9 (11.1)
Fibrosis 0/23 (0.0) 0/9 (0.0)
Well differentiated, n (%) 15/23 (65.2) 4/9 (44.4) 0.43
Moderately differentiated, n (%) 6/23 (26.1) 2/9 (22.2) 1.0
Poorly differentiated, n (%) 2/23 (8.7) 3/9 (33.3) 0.12
Histopathological grading (AJCC), n (%)
G1 15/23 (65.2) 4/9 (44.4) 0.25
G2 6/23 (26.1) 2/9 (22.2)
G3 2/23 (8.7) 3/9 (33.3)
Primary tumour (T) (AJCC), n (%)
Tis 2/23 (8.7) 1/9 (11.1) 0.83
T1 13/23 (56.5) 5/9 (55.6)
T1a 2/23 (8.7) 0/9 (0.0)
T1b 1/23 (4.4) 0/9 (0.0)
T2 1/23 (4.4) 0/9 (0.0)
T3 3/23 (13.0) 1/9 (11.1)
NC 1/23 (4.4) 2/9 (22.2)
p-16 immunohistochemistry positivity, n (%) 1/23 (4.4) 6/9 (66.7) 0.001
E6 gene positivity, n (%) 0/0 (0.0) 5/7 (71.4)
Outcome, died 11/23 (47.8) 3/9 (33.3) 0.69